Orexo receives 2 million EURO in milestone payment for approval of the pain product Rapinyl
The license agreement with ProStrakan Group plc. provides for in addition to the already received up-front license fee payment of 5 million EURO and this milestone payment of 2 million EURO, additional regulatory approval and sales milestone payments, which can total up to 15 million EURO. When ProStrakan introduces Rapinyl on the European market, the agreement also provides for double-digit royalties upon commercial sales. Furthermore, the licensing agreement provides Orexo with the right to - in parallel with ProStrakan - market Rapinyl in the Nordic market.
Rapinyl is a product for the treatment of acute pain. Breakthrough cancer pain is the first indication for Rapinyl. It is based on Orexo´s unique proprietary technology for sublingual administration, where a fast dissolving tablet is placed under the tongue where it rapidly disintegrates into ordered mucoadhesive units of the active substance. This novel pharmaceutical preparation combines the properties of fast dissolution and fast onset of effect.
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.